Similar articles

• Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

  Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators. Wynn D, et al. Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Lancet Neurol. 2010. PMID: 20163990 Clinical Trial.
• Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

  Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Bielekova B, et al. Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6. doi: 10.1073/pnas.0601335103. Epub 2006 Apr 3. Proc Natl Acad Sci U S A. 2006. PMID: 16585503 Free PMC article. Clinical Trial.
• Daclizumab Therapy for Multiple Sclerosis.

  Bielekova B. Bielekova B. Cold Spring Harb Perspect Med. 2019 May 1;9(5):a034470. doi: 10.1101/cshperspect.a034470. Cold Spring Harb Perspect Med. 2019. PMID: 29661806 Free PMC article. Review.
• Multiple sclerosis: pathophysiology revisited.

  Sorensen PS. Sorensen PS. Lancet Neurol. 2005 Jan;4(1):9-10. doi: 10.1016/S1474-4422(04)00948-2. Lancet Neurol. 2005. PMID: 15620850 Review. No abstract available.
• Circulating innate lymphoid cells are unchanged in response to DAC HYP therapy.

  Gillard GO, Saenz SA, Huss DJ, Fontenot JD. Gillard GO, et al. J Neuroimmunol. 2016 May 15;294:41-5. doi: 10.1016/j.jneuroim.2016.03.008. Epub 2016 Mar 29. J Neuroimmunol. 2016. PMID: 27138097